DUBLIN--(BUSINESS WIRE)--The "Influenza Diagnostics Market by Test Type {[Traditional (RIDT, Direct Fluorescent Antibody, Viral Culture, Serology), Molecular [RT-PCR, INAAT (NASBA, LAMP)]}, End User (Hospitals, Laboratories, Academics, Research Institutes) - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
The growth in the influenza diagnostics market is mainly attributed to the factors such as increasing prevalence of influenza, growing awareness for early detection using specific diagnostic tests, development of CLIA-waived POC molecular influenza tests, and shifting focus from centralized laboratories to decentralized point-of-care testing. In addition, advances in genomics and proteomics and emerging markets such as India, Brazil, China, and other countries provide significant growth opportunities for vendors present across the globe.
To provide efficient analysis, the publisher has segmented this market by test type (traditional diagnostic tests, molecular diagnostic tests), end user (hospital & clinical laboratories, diagnostic reference laboratories, academic/research institutes, and others), and geography (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa).
Based on test type, the traditional diagnostic tests segment is estimated to account for the largest share of the overall influenza diagnostics market in 2020. The large share of this segment is primarily attributed to the wide use of rapid influenza diagnostics tests (RIDTs) due to its cost-effectiveness and ability to provide test results in 15- 30 minutes. In addition, the availability of advanced diagnostic immunoassay formats and increasing usage of miniaturized devices in influenza diagnostics are further stimulating the growth of this segment. However, the molecular diagnostic tests segment is expected to grow at the fastest growth rate during the forecast period.
Based on end user, the diagnostic reference laboratories segment is projected to register the fastest CAGR during the forecast period, mainly due to their nature of supporting the diagnosis required in patient care as well as medical research. Moreover, owing to curtailed reimbursements for laboratory testing services, hospitals prefer to outsource their diagnostic testing services to the large commercial laboratories and eliminate associated operational expenses required for maintaining in-house labs, thereby driving the market.
An in-depth analysis of the geographic scenario of the influenza diagnostics market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) along with the coverage of major countries in each region. The North America region is estimated to dominate the global influenza diagnostics market in 2020, followed by Europe, and Asia Pacific. The factors such as increasing incidence of influenza, higher adoption for technologically advanced diagnostic products, and increase in the research and development activities for influenza supported the largest share of the North America region in the influenza diagnostics market.
Market Insights
Drivers
- Increasing Global Prevalence of Influenza
- Growing Awareness of Early Influenza Diagnosis
- Development of CLIA-Waived POC Molecular Influenza Tests
- Shift in Focus from Centralized Laboratories to Point-of-Care Testing Services
Restraints
- Technical Requirements and Regulatory Process for High or Moderate Complexity Tests
Opportunities
- Advances in Genomics and Proteomics
- Growth Opportunities in Emerging Economies
Challenges
- Unfavorable and Inadequate Reimbursement Scenario
Companies Profiled
- Thermo Fisher Scientific, Inc.
- Abbott Laboratories
- Danaher Corporation
- Bio-Rad Laboratories, Inc.
- BioMrieux S.A.
- F. Hoffmann-La Roche Ltd.
- Becton, Dickinson and Company
- Meridian Bioscience, Inc.
- Quidel Corporation
- Hologic, Inc.
- Siemens Healthineers AG (Subsidiary of Siemens AG)
- Luminex Corporation
- GenMark Diagnostics, Inc.
- Altona Diagnostics GmbH
- SA Scientific, Ltd.
- Sekisui Diagnostics, LLC
- CorisBioconcept SPRL
- ELITech Group
- Mast Group, Ltd.
- Response Biomedical Corporation
- Germaine Laboratories, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/p2kqcg
